trial · primary record
Ublituximab
Schizophrenia
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 60 |
| Primary completion | 2029-03-01 |
| Primary endpoint | Percentage of Participants with at Least 20% Reduction From Baseline in PANSS Total Score |
| Registry ID | NCT07680946 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:41:44.047Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07680946
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Ublituximab · compound